Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

India’s IP Policy: India’s Lead Biotech Innovator Expresses Concern

shutterstock_2103563

Kiran Mazumdar-Shaw, chairperson and managing director of India’s largest biotechnology company Biocon, expressed concern with India’s innovation environment in a recent interview with Livemint.  When asked if the Indian government fosters innovation Ms. Shaw responded: “I am very concerned about the wrong signals we are sending to the world. We have not done anything substantial to build India as a strong global economy. We have wasted a lot of opportunities. We behave like the world Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patent Trolls and Patent Litigation: The GAO Weighs In

shutterstock_26191726

Patent troll litigation alarmist were likely disappointed by the GAO report.  While the public discourse may have already concluded that patent trolls have laid waste to the innovative landscape by creating a patent litigation crisis, the GAO report does not find much evidence to support such claims. Patent troll litigation is not running rampant.  The GAO analyzed a sample of 500 patent infringement lawsuits from 2007 to 2011 and found that companies that make products (operating Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

What a Patent is Not

shutterstock_2103563

‘Patent trolls.’  ‘Patients over patents.’  ‘Do Not Patent My Genes.’  ‘Patents ate my baby.’  Ok, so I made the last one up.  The emphasis on patents in the public discourse has reached a new high.  Yet, many commentators get the basics wrong.  Here are a few things that a patent is not. A patent is not ownership of a thing, whether it is life, genes, viruses, computer code, or any other animate or inanimate object.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Fresenius v. Baxter: BIO files Amicus Brief in Federal Circuit

shutterstock_1092009

The Biotechnology Industry Organization filed an amicus brief at the Federal Circuit in the case of Fresenius v. Baxter: BIO is concerned that the panel decision could have a number of unintended consequences, such as incentivizing defendants (or declaratory judgment plaintiffs) to employ dilatory tactics in the federal courts while re-arguing already-decided issues under claim construction more favorable to the patent challenger and lower burden-of-proof standards in the PTO.  Courts and parties may be forced Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Bayh-Dole and Technology Transfer Continue to Deliver

87881842

The Association of University Technology Managers released the 2012 AUTM U.S. Licensing Activity Survey Highlights which provides data on respondents from “161 universities, 32 hospitals and research institutes, and one third-party technology investment firm” (a response rate of 65%).  Here are some of the highlights: Start-Ups and Products: • 705 startup companies formed (+5.1% [over last year]), 554 of which had their primary place of business in the licensing institution’s home state (+13.8% [over last Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,